Last checked at 24 Nov 2020 07:00
24 November 2020
Venture Life Group plc
("Venture Life" or the "Company")
PDMR Dealings and Issue of Equity
Further to the announcement made on 20 November 2020 and as outlined in the Company's circular of the same date the Company notifies the following PDMR dealings.
· On 20 November 2020, Jerry Randall, Sharon Daly and Gianluca Braguti and certain of his associates conditionally agreed to sell 2,752,751 Ordinary Shares (including Ordinary Shares arising on exercise of EMI Options as outlined below), 1,877,863 Ordinary Shares (also including Ordinary Shares arising on exercise of EMI Options as outlined below) and 3,542,729 Ordinary Shares in the Company, respectively.
· On 23 November 2020, Jerry Randall, CEO, and Sharon Daly, CCO, have conditionally exercised a total of 1,735,774 EMI Options. Of these EMI Options, 1,411,400 have been exercised at a price per Ordinary Share of 45 pence and 324,374 have been exercised at a price per Ordinary Share of 41 pence.
Both the issue of options and the sale of shares are conditional upon the fundraising, announced at 13:00 on 20 November 2020 (RNS No.0547G) being approved at a General Meeting of Shareholders to be held on 8 December 2020 and the Placing Shares and Open Offer Shares being admitted to trading on AIM on 9 December 2020.
If the resolutions that are to be put to Shareholders are passed at the General Meeting, an application will be made to the London Stock Exchange for the 1,735,774 new Ordinary Shares resulting from the option exercise as well as the Placing Shares and Open Offer Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading will commence at 8.00 a.m. on 9 December 2020. The Company will make a further announcement in this regard once the conditions have been met.
Capitalised terms used, but not defined, in this announcement have the same meaning as set out in the Circular.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004Jerry Randall, Chief Executive OfficerAndrew Waters, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397 8900Stephen Keys / Camilla Hume/ Cameron MacRitchie (Corporate Finance)Russell Kerr / Michael Johnson (Sales)
N+1 Singer (Joint Broker)Shaun Dobson / Carlo Spingardi (Corporate Finance) +44 (0) 20 7496 3000Jonathan Dighe (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | 1. Jerry Randall
|
2 | Reason for the notification | |
a) | Position/status | 1. Chief Executive Officer
|
b) | Initial notification /Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Venture Life Group plc |
b) | LEI | 213800S8CZUPLAB2KC70 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.3p each in Venture Life Group plc |
b) | Identification code | GB00BFPM8908 |
c) | Nature of the transaction | Conditional Exercise of EMI Share Options and conditional Sales of Shares |
d)
| Price and volumes | Shares 2,752,751 shares (including Ordinary Shares arising on exercise of EMI Options as detailed below) to be sold at a price of £0.90 per Ordinary Share Options 705,700 options have been exercised at a price of £0.45 per Ordinary Share and 162,187 options have been exercised at a price of £0.41 per Ordinary Share.
|
e)
| Aggregated information - Aggregated volume - Price | See above
|
f) | Date of the transaction | 20 November 2020 for the sale of shares (including Ordinary shares arising on exercise of options) 23 November for the exercise of options |
g) | Place of the transaction | London Stock Exchange |
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | 2. Sharon Daly
|
2 | Reason for the notification | |
a) | Position/status | 2. Chief Commercial Officer
|
b) | Initial notification /Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Venture Life Group plc |
b) | LEI | 213800S8CZUPLAB2KC70 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.3p each in Venture Life Group plc |
b) | Identification code | GB00BFPM8908 |
c) | Nature of the transaction | Conditional Exercise of EMI Share Options and conditional Sales of Shares |
d)
| Price and volumes | Shares 1,877,864 shares to be sold to be sold at a price of £0.90 per Ordinary Share (including Ordinary Shares arising on exercise of EMI Options as below) Options 705,700 options have been exercised at a price of £0.45 per Ordinary Share and 162,187 options have been exercised at a price of £0.41 per Ordinary Share.
|
e)
| Aggregated information - Aggregated volume - Price | See above
|
f) | Date of the transaction | 20 November 2020 for the sale of shares (including Ordinary shares arising on exercise of options) 23 November for the exercise of options |
g) | Place of the transaction | London Stock Exchange |
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | 3. Gianluca Braguti and certain of his associates |
2 | Reason for the notification | |
a) | Position/status | 3. Chief Manufacturing Officer |
b) | Initial notification /Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Venture Life Group plc |
b) | LEI | 213800S8CZUPLAB2KC70 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.3p each in Venture Life Group plc |
b) | Identification code | GB00BFPM8908 |
c) | Nature of the transaction | Conditional Sales of Shares |
d)
| Price and volumes | Shares 3,542,729 shares to be sold will be sold at a price of £0.90 per Ordinary Share |
e)
| Aggregated information - Aggregated volume - Price | See above
|
f) | Date of the transaction | 20 November 2020 |
g) | Place of the transaction | London Stock Exchange |